Transthyretin Amyloidosis clinical trials

Explore recruiting transthyretin amyloidosis clinical trials.

Recruiting transthyretin amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Transthyretin Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

i-Care; Quantitative-imaging in cardiac transthyretin amyloidosis

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Netherlands, Belgium, Cyprus, Spain, Portugal, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Bulgaria, Portugal, Germany, Italy, Netherlands, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to establish the bioequivalence of free acid tafamidis 61 mg capsule and tablet, and evaluate the safety and tolerability of the 61 mg tablet in healthy adults

Belgium

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions

Belgium

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Denmark, Belgium, Italy, Sweden, Czechia, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Transthyretin Amyloidosis trials by city

Transthyretin Amyloidosis clinical trials

Recruiting transthyretin amyloidosis studies right now

Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

Molecular Imaging of Primary Amyloid Cardiomyopathy

Ultrasound Therapy In Cardiac Amyloidosis

Also recruiting in Europe

i-Care; Quantitative-imaging in cardiac transthyretin amyloidosis

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

A study to establish the bioequivalence of free acid tafamidis 61 mg capsule and tablet, and evaluate the safety and tolerability of the 61 mg tablet in healthy adults

A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Transthyretin Amyloidosis trials by city

Other conditions